The Chemours Company (NYSE:CC) Given Average Recommendation of “Hold” by Analysts

The Chemours Company (NYSE:CC) has been given an average recommendation of “Hold” by the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.10.

Several analysts recently weighed in on CC shares. Mizuho set a $22.00 price objective on Chemours in a report on Wednesday, August 5th. UBS Group reiterated a “neutral” rating and set a $18.00 target price (down from $29.00) on shares of Chemours in a report on Monday, August 10th. Royal Bank Of Canada cut their target price on shares of Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. reduced their price target on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 13th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $17.00 price target on shares of Chemours in a research report on Thursday, August 13th.

Insiders Place Their Bets

In related news, CEO Denise Dignam purchased 3,378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Shane Hostetter purchased 3,350 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the acquisition, the chief financial officer directly owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 8,663 shares of company stock worth $130,601 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Chemours

Several institutional investors have recently bought and sold shares of CC. Parallel Advisors LLC increased its position in shares of Chemours by 10.9% during the first quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 527 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of Chemours by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock worth $404,000 after purchasing an additional 600 shares in the last quarter. PFG Investments LLC boosted its position in shares of Chemours by 7.6% in the 4th quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock worth $147,000 after purchasing an additional 883 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Chemours by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock worth $899,000 after buying an additional 932 shares during the last quarter. Finally, Man Group plc grew its stake in Chemours by 0.4% during the 2nd quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after buying an additional 979 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Chemours Stock Performance

NYSE CC opened at $15.85 on Friday. The business’s 50 day moving average price is $17.52 and its 200-day moving average price is $20.00. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The company has a market cap of $2.39 billion, a P/E ratio of -8.30 and a beta of 1.43. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66.

Chemours (NYSE:CC) last announced its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same period in the previous year, the business earned ($2.54) EPS. Sell-side analysts predict that Chemours will post 0.87 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours’s payout ratio is -18.32%.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.